Neoplasms

Blood and Lymph Conditions

All Conditions

Symptoms and General Pathology

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Leukemia, Myeloid, Chronic-Phase

Neoplasms by Histologic Type

Myeloproliferative Disorders

Bone Marrow Diseases

Hematologic Diseases

Chronic Disease

Disease Attributes

Myeloid Leukemia

Chronic Graft Versus Host Disease

Chronic Myeloid Leukemia

Chronic Myeloproliferative Disorders

All Drugs and Chemicals

Antineoplastic Agents

Nilotinib

Imatinib Mesylate

patients will be followed for 3 months with access to eMedonline

patients will be followed for 3 months with no access to eMedonline

patients will be followed for 3 months but will not use eMedonline

no access to eMedonline

patients will be given access to eMedonline use for 3 months

eMedonline access

Robert Wehbie, MD

This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.

This is a randomized, controlled pilot study to introduce eMedonline telemonitoring technology to CML patients taking Gleevec or Tasigna. eMedonline will be used to automatically collect time-dose specific medication data for individual patients, including dosing times, missed doses, adverse events and e-diary data. All data will be available to research staff for remote review via Web interface. Adverse events and non-adherence will prompt interventions including supportive care counseling.

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib)Therapy

Patients are stratified to one of two groups: Group 1 is pateints on Gleevec or Tasigna who have been on drug less than 6 months; Group 2 is patients on Gleevec or Tasigna who have been on drug for equal to or more than 6 months.

Group 1 is then divided into 2 groups: one using eMedonline for 3 months and the other not using eMedonline for 3 months. A crossover survey and pill counts will be done at the 3 month timepoint and then the groups will switch their access status to eMedonline.

Northwestern University

Rex Cancer Center, Raleigh, NC

patients will have access to eMedonline access for 3 months

Telemonitoring Study - for Chronic Myeloid Leukemia (CML)

Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy

Patients are stratified to one of two groups: Group 1 is patients on Gleevec or Tasigna who have been on drug less than 6 months; Group 2 is patients on Gleevec or Tasigna who have been on drug for equal to or more than 6 months.

Group 1 is then divided into 2 groups: one using eMedonline for 3 months and the other not using eMedonline for 3 months. A crossover survey and pill counts will be done at the 3 month timepoint and then the groups will switch their access status to eMedonline.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy	NCT01490775	Chronic Phase C...	no access to eM... eMedonline acce...	18 Years -	Rex Cancer Center, Raleigh, NC
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy	NCT01490775	Chronic Phase C...	no access to eM... eMedonline acce...	18 Years -	Rex Cancer Center, Raleigh, NC
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy	NCT01490775	Chronic Phase C...	no access to eM... eMedonline acce...	18 Years -	Rex Cancer Center, Raleigh, NC
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)	NCT01490983	Chronic Myeloid...	no access to eM... eMedonline acce...	18 Years -	Rex Cancer Center, Raleigh, NC

Spots Global Cancer Trial Database for no access to emedonline